GlassScriptPhysician profile
Sumit Sawhney
NPI 1548263353
$102,815.37
in general payments reported to CMS, 2019-2025
88 companies · $7,888 in 2025
The $7,888 reported for 2025 was more than what 86% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $16K · 2021: $21K · 2022: $19K · 2023: $9,674 · 2024: $9,539 · 2025: $7,888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $6,207 · Travel and Lodging: $2,319 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Honoraria: $1,500 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $14,886.50 |
| Food and Beverage | $6,206.52 |
| Travel and Lodging | $2,318.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Honoraria | $1,500.00 |
| Education | $189.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16,975.63 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Janssen Scientific Affairs, LLC | $8,865.44 | 2019-2023 | Imbruvica |
| Janssen Biotech, INC. | $7,587.71 | 2019-2025 | Tecvayli, Darzalex, Erleada |
| Genzyme Corporation | $6,409.40 | 2019-2025 | |
| Eisai INC. | $5,407.71 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $5,332.06 | 2022-2024 | Monoferric |
| Sun Pharmaceutical Industries INC. | $4,863.50 | 2019-2023 | |
| Jazz Pharmaceuticals INC. | $4,214.59 | 2019-2025 | |
| Athenex Pharmaceutical Division, LLC | $4,025.00 | 2020 | |
| Glaxosmithkline, LLC. | $3,906.70 | 2020-2025 | Ojjaara, Blenrep, Shingrix |
| Ipsen Biopharmaceuticals, INC | $3,214.09 | 2019-2023 | Tazverik |
| Avyxa Pharma, LLC | $3,015.22 | 2025 | |
| Amgen INC. | $2,890.71 | 2019-2023 | Lumakras, Xgeva, Nplate |
| Beigene USA, INC. | $2,701.06 | 2020-2024 | Brukinsa |
| Rigel Pharmaceuticals, INC. | $1,666.34 | 2019-2023 | Rezlidhia, Tavalisse |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eagle Pharmaceuticals, INC. | $1,509.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,506.32 | 2019-2025 | Iclusig, Fruzaqla, Alunbrig |
| Pfizer INC. | $1,502.55 | 2019-2025 | |
| Taiho Oncology, INC. | $1,425.06 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $1,361.93 | 2019-2025 | Opdivo, Opdualag, Reblozyl |
| Puma Biotechnology, INC. | $1,303.29 | 2019-2023 | Nerlynx |
| Novocure INC. | $1,048.00 | 2019 | |
| Exelixis INC. | $1,036.41 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $847.91 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $705.93 | 2019-2025 | Jakafi, Zynyz, Monjuvi |
| Daiichi Sankyo INC. | $651.19 | 2019-2022 | |
| Seagen INC. | $606.38 | 2019-2023 | Tivdak, Padcev, Tukysa |
| Abbvie INC. | $552.76 | 2019-2025 | Venclexta |
| Beigene, LTD. | $525.00 | 2021 | |
| Merck Sharp & Dohme LLC | $497.87 | 2019-2023 | Keytruda, Lynparza |
| Genentech USA, INC. | $475.89 | 2019-2025 | Tecentriq |
| Celgene Corporation | $458.91 | 2019-2025 | Reblozyl |
| Dr.Reddy'S Laboratories,INC. | $400.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $394.51 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $385.98 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $371.36 | 2019-2022 | |
| Foundation Medicine, INC. | $346.63 | 2019-2023 | |
| Array Biopharma INC | $233.10 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Gilead Sciences, INC. | $223.89 | 2019-2025 | Trodelvy |
| Astellas Pharma US INC | $215.64 | 2019-2020 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Tersera Therapeutics LLC | $176.98 | 2019-2025 | Zoladex |
| Ucb, INC. | $162.01 | 2025 | |
| Karyopharm Therapeutics INC. | $149.88 | 2020-2023 | Xpovio |
| Dova Pharmaceuticals | $148.22 | 2019-2021 | |
| Deciphera Pharmaceuticals INC. | $141.63 | 2020-2023 | Qinlock |
| Tolmar Pharmaceuticals, INC. | $139.21 | 2022 | |
| Adaptive Biotechnologies Corporation | $129.81 | 2022-2025 | Clonoseq |
| Stemline Therapeutics INC. | $126.58 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $116.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $112.89 | 2019-2021 | |
| Sobi, INC | $110.91 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.13 | 2019-2020 | |
| Comsort, INC | $100.00 | 2019 | |
| Intrinsiq Specialty Solutions, INC. | $100.00 | 2020 | |
| Cardinal Health 110 LLC | $100.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $94.27 | 2022-2023 | Libtayo |
| Coherus Oncology, INC. | $84.13 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $73.01 | 2019-2020 | |
| Caris Mpi, INC. | $73.00 | 2025 | Mi Cancer Seek |
| Servier Pharmaceuticals LLC | $70.12 | 2023 | |
| Aurobindo Pharma USA, INC. | $69.16 | 2019-2020 | |
| Verastem, INC. | $55.94 | 2019-2020 | |
| Clovis Oncology, INC. | $43.62 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $42.82 | 2023-2024 | Avastin, Neulasta, Neupogen |
| Mirati Therapeutics, INC. | $42.61 | 2023 | Krazati |
| Nuvation Bio INC. | $31.78 | 2025 | Ibtrozi |
| Advanced Accelerator Applications | $31.49 | 2019-2020 | |
| Blue Earth Diagnostics | $25.99 | 2021-2023 | |
| Kite Pharma, INC. | $24.81 | 2023 | |
| Aveo Pharmaceuticals, INC. | $22.71 | 2022 | |
| Immunogen, INC. | $22.14 | 2023 | Elahere |
| Tolmar, INC. | $21.40 | 2024 | |
| Organon LLC | $21.21 | 2022 | |
| Geron Corporation | $21.00 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $20.60 | 2025 | Besremi |
| Verity Pharmaceuticals INC. | $20.44 | 2022 | |
| Kyowa Kirin, INC. | $19.76 | 2020 | |
| Acceleron Pharma, INC. | $18.13 | 2020 | |
| Ethicon US, LLC | $17.28 | 2019 | |
| Myovant Sciences INC. | $17.13 | 2021 | |
| Pharmaand Gmbh | $13.20 | 2025 | Rubraca |
| Octapharma USA, INC. | $13.02 | 2020 | |
| Agios Pharmaceuticals, INC. | $12.96 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $11.18 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$84,222.10 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Sawhney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.